leukapheresis
a2 biotherapeutics
['basecamp-1', 'car t']
the basecamp-1 study is currently enrolling participants to explore the feasibility of manufacturing a novel car t-cell therapy with a target antigen activator and a hla loh-based blocker. #asco22 
CGTLive™ delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.